JP5734870B2 - ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途 - Google Patents

２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途 Download PDF

Info

Publication number: JP5734870B2
Authority: JP; Japan
Prior art keywords: group; dihydro; pyrazol; methyl; oxo
Prior art date: 2008-12-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2011542886A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012513976A (ja

Inventor

アルタンビユルジエ，ジヤン−ミシエル

フオツセ，バレリイ

イリアノ，ステフアンヌ

マネツト，ジエラルデインヌ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi SA

Original Assignee

Sanofi SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-29

Filing date

2009-12-24

Publication date

2015-06-17

2008-12-29 Priority claimed from FR0807474A external-priority patent/FR2940651B1/fr

2009-08-28 Priority claimed from FR0904092A external-priority patent/FR2949466A1/fr

2009-12-24 Application filed by Sanofi SA filed Critical Sanofi SA

2012-06-21 Publication of JP2012513976A publication Critical patent/JP2012513976A/ja

2015-06-17 Application granted granted Critical

2015-06-17 Publication of JP5734870B2 publication Critical patent/JP5734870B2/ja

Status Expired - Fee Related legal-status Critical Current

2029-12-24 Anticipated expiration legal-status Critical

Links

0 CCC(C)(*C)C(C(*)=O)*(N=O)=O Chemical compound CCC(C)(*C)C(C(*)=O)*(N=O)=O 0.000 description 2
LYIXZKAYJMYXOT-UHFFFAOYSA-N CN(C1OSO1)C1CCCC1 Chemical compound CN(C1OSO1)C1CCCC1 LYIXZKAYJMYXOT-UHFFFAOYSA-N 0.000 description 1
RNJGIOWAXINFKY-UHFFFAOYSA-N CNC(CC([N+]([O-])=O)=O)=O Chemical compound CNC(CC([N+]([O-])=O)=O)=O RNJGIOWAXINFKY-UHFFFAOYSA-N 0.000 description 1
WGPWWZBZNKGIFH-RXMQYKEDSA-N C[C@H]1C=[O]CNNC1 Chemical compound C[C@H]1C=[O]CNNC1 WGPWWZBZNKGIFH-RXMQYKEDSA-N 0.000 description 1
JQZCSHOZSRTQKL-UHFFFAOYSA-N O=C1[I]=CNN1 Chemical compound O=C1[I]=CNN1 JQZCSHOZSRTQKL-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Vascular Medicine (AREA)

JP2011542886A 2008-12-29 2009-12-24 ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途 Expired - Fee Related JP5734870B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
FR0807474		2008-12-29
FR0807474A FR2940651B1 (fr)	2008-12-29	2008-12-29	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
FR0904092		2009-08-28
FR0904092A FR2949466A1 (fr)	2009-08-28	2009-08-28	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
PCT/FR2009/052691 WO2010076524A2 (fr)	2008-12-29	2009-12-24	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif

Publications (2)

Publication Number	Publication Date
JP2012513976A JP2012513976A (ja)	2012-06-21
JP5734870B2 true JP5734870B2 (ja)	2015-06-17

Family

ID=42008610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2011542886A Expired - Fee Related JP5734870B2 (ja)	2008-12-29	2009-12-24	２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途

Country Status (35)

Country	Link
US (1)	US8541455B2 (fr)
EP (1)	EP2382205B1 (fr)
JP (1)	JP5734870B2 (fr)
KR (1)	KR20110099786A (fr)
CN (1)	CN102333769B (fr)
AR (1)	AR074915A1 (fr)
AU (1)	AU2009334569B2 (fr)
BR (1)	BRPI0924060A8 (fr)
CA (1)	CA2748411A1 (fr)
CL (1)	CL2011001496A1 (fr)
CO (1)	CO6400141A2 (fr)
CR (1)	CR20110361A (fr)
CY (1)	CY1115368T1 (fr)
DK (1)	DK2382205T3 (fr)
EA (1)	EA019591B1 (fr)
EC (1)	ECSP11011155A (fr)
ES (1)	ES2481042T3 (fr)
HR (1)	HRP20140680T1 (fr)
IL (1)	IL213789A (fr)
MA (1)	MA32976B1 (fr)
MX (1)	MX2011007054A (fr)
MY (1)	MY179093A (fr)
NZ (1)	NZ593751A (fr)
PA (1)	PA8856201A1 (fr)
PE (1)	PE20120416A1 (fr)
PL (1)	PL2382205T3 (fr)
PT (1)	PT2382205E (fr)
SG (1)	SG172803A1 (fr)
SI (1)	SI2382205T1 (fr)
SM (1)	SMT201400097B (fr)
TN (1)	TN2011000267A1 (fr)
TW (1)	TWI482763B (fr)
UY (1)	UY32369A (fr)
WO (1)	WO2010076524A2 (fr)
ZA (1)	ZA201104783B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010076525A1 (fr)	2008-12-29	2010-07-08	Sanofi-Aventis	Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
WO2012133783A1 (fr) *	2011-03-31	2012-10-04	キッセイ薬品工業株式会社	Procédé de production de dérivés benzylpyrazole et intermédiaire de production de ceux-ci
ES2699404T3 (es) *	2012-03-30	2019-02-11	Daiichi Sankyo Co Ltd	Derivado de 4-alcanoilamino-3-pirazolona
PT2978752T (pt) *	2013-03-29	2018-03-09	Takeda Pharmaceuticals Co	Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e o seu uso como inibidores de phd
DE102016223133A1 (de)	2016-11-23	2018-05-24	Deere & Company	Geschwindigkeitskontrolle einer Erntemaschine
AR121621A1 (es) *	2020-03-20	2022-06-22	Akebia Therapeutics Inc	Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4023488A1 (de) *	1990-07-24	1992-01-30	Bayer Ag	1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en)	1993-03-30	1998-05-12	The Dupont Merck Pharmaceutical Company	Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
AU2004275694B2 (en)	2003-06-30	2008-03-06	Bizbiotech Co., Ltd.	Compounds, compositions and methods
DE102005019712A1 (de) *	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
AR059733A1 (es)	2006-03-07	2008-04-23	Smithkline Beecham Corp	Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
CN101528752A (zh)	2006-10-16	2009-09-09	辉瑞产品公司	治疗性吡唑基噻吩并吡啶
DE102006050516A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
CA2687306A1 (fr)	2007-05-18	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Derives de pyrazole a substitution heteroaryle utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese

2009
- 2009-12-24 KR KR1020117017676A patent/KR20110099786A/ko not_active Abandoned
- 2009-12-24 HR HRP20140680AT patent/HRP20140680T1/hr unknown
- 2009-12-24 PT PT98057896T patent/PT2382205E/pt unknown
- 2009-12-24 SG SG2011047503A patent/SG172803A1/en unknown
- 2009-12-24 DK DK09805789.6T patent/DK2382205T3/da active
- 2009-12-24 MX MX2011007054A patent/MX2011007054A/es active IP Right Grant
- 2009-12-24 SI SI200930983T patent/SI2382205T1/sl unknown
- 2009-12-24 CA CA2748411A patent/CA2748411A1/fr not_active Abandoned
- 2009-12-24 AU AU2009334569A patent/AU2009334569B2/en not_active Ceased
- 2009-12-24 BR BRPI0924060A patent/BRPI0924060A8/pt not_active IP Right Cessation
- 2009-12-24 EP EP09805789.6A patent/EP2382205B1/fr active Active
- 2009-12-24 CN CN200980157590.6A patent/CN102333769B/zh not_active Expired - Fee Related
- 2009-12-24 PE PE2011001292A patent/PE20120416A1/es not_active Application Discontinuation
- 2009-12-24 MA MA34027A patent/MA32976B1/fr unknown
- 2009-12-24 EA EA201170899A patent/EA019591B1/ru not_active IP Right Cessation
- 2009-12-24 NZ NZ593751A patent/NZ593751A/xx not_active IP Right Cessation
- 2009-12-24 WO PCT/FR2009/052691 patent/WO2010076524A2/fr not_active Ceased
- 2009-12-24 ES ES09805789.6T patent/ES2481042T3/es active Active
- 2009-12-24 PL PL09805789T patent/PL2382205T3/pl unknown
- 2009-12-24 MY MYPI2011003012A patent/MY179093A/en unknown
- 2009-12-24 JP JP2011542886A patent/JP5734870B2/ja not_active Expired - Fee Related
- 2009-12-28 AR ARP090105126A patent/AR074915A1/es unknown
- 2009-12-28 TW TW098145336A patent/TWI482763B/zh not_active IP Right Cessation
- 2009-12-29 PA PA20098856201A patent/PA8856201A1/es unknown
- 2009-12-29 UY UY0001032369A patent/UY32369A/es not_active Application Discontinuation
2011
- 2011-05-24 TN TN2011000267A patent/TN2011000267A1/fr unknown
- 2011-06-17 CL CL2011001496A patent/CL2011001496A1/es unknown
- 2011-06-22 EC EC2011011155A patent/ECSP11011155A/es unknown
- 2011-06-23 CR CR20110361A patent/CR20110361A/es unknown
- 2011-06-27 IL IL213789A patent/IL213789A/en not_active IP Right Cessation
- 2011-06-28 ZA ZA2011/04783A patent/ZA201104783B/en unknown
- 2011-06-29 CO CO11081326A patent/CO6400141A2/es active IP Right Grant
- 2011-06-29 US US13/172,305 patent/US8541455B2/en not_active Expired - Fee Related
2014
- 2014-07-22 SM SM201400097T patent/SMT201400097B/xx unknown
- 2014-07-23 CY CY20141100553T patent/CY1115368T1/el unknown

Also Published As

Publication number	Publication date
CN102333769A (zh)	2012-01-25
AU2009334569A1 (en)	2011-07-21
ES2481042T3 (es)	2014-07-29
PA8856201A1 (es)	2010-07-27
EP2382205A2 (fr)	2011-11-02
EA201170899A1 (ru)	2012-02-28
ECSP11011155A (es)	2011-07-29
BRPI0924060A2 (pt)	2015-07-07
EA019591B1 (ru)	2014-04-30
CO6400141A2 (es)	2012-03-15
HRP20140680T1 (hr)	2014-10-10
CL2011001496A1 (es)	2011-10-28
WO2010076524A2 (fr)	2010-07-08
AU2009334569B2 (en)	2016-02-25
PE20120416A1 (es)	2012-05-08
KR20110099786A (ko)	2011-09-08
TWI482763B (zh)	2015-05-01
ZA201104783B (en)	2012-09-26
MA32976B1 (fr)	2012-01-02
US20110294788A1 (en)	2011-12-01
AR074915A1 (es)	2011-02-23
DK2382205T3 (da)	2014-07-28
UY32369A (es)	2010-07-30
CR20110361A (es)	2011-09-20
CA2748411A1 (fr)	2010-07-08
US8541455B2 (en)	2013-09-24
WO2010076524A3 (fr)	2010-08-26
SI2382205T1 (sl)	2014-08-29
JP2012513976A (ja)	2012-06-21
TN2011000267A1 (fr)	2012-12-17
EP2382205B1 (fr)	2014-04-23
PT2382205E (pt)	2014-07-28
MX2011007054A (es)	2011-11-29
SMT201400097B (it)	2014-09-08
NZ593751A (en)	2013-08-30
MY179093A (en)	2020-10-27
CN102333769B (zh)	2014-08-27
PL2382205T3 (pl)	2014-09-30
TW201028391A (en)	2010-08-01
IL213789A (en)	2014-11-30
BRPI0924060A8 (pt)	2015-09-29
CY1115368T1 (el)	2017-01-04
SG172803A1 (en)	2011-08-29
IL213789A0 (en)	2011-07-31

Legal Events

Date	Code	Title	Description
2012-10-25	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121024
2014-03-12	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311
2014-05-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140529
2014-10-29	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141028
2014-12-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141211
2015-03-31	TRDD	Decision of grant or rejection written
2015-04-08	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407
2015-04-23	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150415
2015-04-24	R150	Certificate of patent or registration of utility model	Ref document number: 5734870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2018-04-24	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
ME01296B (me)	2013-12-20	Derivati 4-(2-amino-1-hidroksietil) fenol kao agonisti beta-2 adrenergičkih receptora
JP5734870B2 (ja)	2015-06-17	２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途
EP1539748A1 (fr)	2005-06-15	Derives de c2-phenylpyridine-4-yl en tant qu'inhibiteurs d'alk5
US9359329B2 (en)	2016-06-07	Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof
ES2259419T3 (es)	2006-10-01	Imidazo(1,2-a)piridinas.
JP2009523772A (ja)	2009-06-25	新規環状尿素誘導体、これらの調製およびキナーゼ阻害剤としてのこれらの医薬的使用
JP5222731B2 (ja)	2013-06-26	キナーゼ阻害薬として活性な置換ピロロ−ピラゾール誘導体
RU2472792C2 (ru)	2013-01-20	Соединения 2-(2-оксоиндолин-3-илиден)метил-5-(2-гидрокси-3-морфолин-4-илпропил)-6,7 дигидро-1-н-пиррол[3,2-с]пиридин-4(5н)-она и их применение в качестве ингибиторов протеинкиназы
US20060074244A1 (en)	2006-04-06	Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
US20060004051A1 (en)	2006-01-05	Compounds
HK1163678A (en)	2012-09-14	Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
HK1163678B (en)	2014-11-21	Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
FR2949466A1 (fr)	2011-03-04	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
FR2940651A1 (fr)	2010-07-02	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
HK1163679B (en)	2015-05-08	Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof